Inflammatory Bowel Disease (IBD) Therapeutics

Inflammatory Bowel Disease (IBD) Therapeutics

Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach US$32.8 Billion by 2030

The global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$23.2 Billion in the year 2023, is expected to reach US$32.8 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. TNF inhibitors, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 Billion by the end of the analysis period. Growth in the Anti-integrin segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.1 Billion While China is Forecast to Grow at 8.2% CAGR

The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$6.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Inflammatory Bowel Disease (IBD) Therapeutics - Key Trends and Drivers

Inflammatory Bowel Disease (IBD) therapeutics encompasses a range of treatments designed to manage and alleviate the symptoms of chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn`s disease and ulcerative colitis. These conditions cause severe inflammation, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, and weight loss. The primary goal of IBD therapeutics is to induce and maintain remission, reduce inflammation, and improve patients` quality of life. Treatment options include aminosalicylates, corticosteroids, immunomodulators, biologics, and, more recently, small molecule drugs. Biologics, which target specific components of the immune system, have revolutionized IBD treatment, providing relief for patients who do not respond to traditional therapies. However, the complexity of IBD, with its varying presentations and patient responses, necessitates a personalized approach to treatment.

Technological advancements and ongoing research are significantly impacting the IBD therapeutics landscape. The development of novel biologic therapies and biosimilars has expanded the range of treatment options available to patients. These therapies, including TNF inhibitors, integrin inhibitors, and interleukin inhibitors, offer targeted mechanisms of action that help control inflammation more effectively and with fewer side effects than conventional treatments. Additionally, advancements in precision medicine and pharmacogenomics are enabling more personalized treatment strategies, optimizing therapeutic outcomes based on individual patient profiles. Non-invasive diagnostic tools, such as advanced imaging techniques and biomarkers, are improving the ability to monitor disease activity and treatment response, allowing for more timely and accurate adjustments to therapeutic regimens. Furthermore, digital health technologies, including mobile health apps and telemedicine, are enhancing patient management and adherence to treatment plans by facilitating better communication between patients and healthcare providers.

The growth in the IBD therapeutics market is driven by several factors, including the increasing prevalence of IBD, technological innovations, and greater awareness and diagnosis of the condition. The rising incidence of IBD globally, particularly in developed regions, is significantly expanding the patient population in need of effective treatments. Technological advancements in biologic therapies and the development of biosimilars are reducing treatment costs and making advanced therapies more accessible. The integration of precision medicine into IBD treatment protocols is leading to more effective and personalized therapeutic approaches, improving patient outcomes and satisfaction. Additionally, the adoption of digital health technologies is facilitating better disease management and patient engagement, driving adherence to treatment plans. Regulatory support for novel therapies and expedited approval processes for new drugs are also contributing to market growth. Moreover, ongoing clinical trials and research into the pathophysiology of IBD are paving the way for the development of next-generation therapeutics, promising even more effective and targeted treatment options in the future. These combined factors underscore the dynamic and rapidly evolving nature of the IBD therapeutics market.

Select Competitors (Total 69 Featured) -

• 4SC AG
• Abbott Nutrition
• AbbVie, Inc.
• Ablynx NV
• Active Biotech AB
• Alfasigma S.p.A.
• Allergan PLC
• Allergan PLC
• Amgen, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Athersys, Inc.
• Atlantic Healthcare plc
• Avaxia Biologics, Inc.
• Biosafe Systems, LLC
• Boehringer Ingelheim GmbH
• Cadila Healthcare Ltd.
• Celgene Corporation
• Celltrion, Inc.
• Cipla Ltd.
• Coherus Biosciences, Inc.
• Cosmo Pharmaceuticals NV
• Dr. Falk Pharma GmbH
• EA Pharma Co., Ltd.
• Eddingpharm
• EPIRUS Biopharmaceuticals, Inc.
• F. Hoffmann-La Roche AG
• F. Hoffmann-La Roche AG
• Galapagos NV
• Giaconda Ltd.
• Google LLC
• Immunic, Inc.
• InDex Pharmaceuticals Holding AB
• Infinity Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Janssen Biotech, Inc.
• Johnson & Johnson
• Kissei Pharmaceutical Co., Ltd.
• LG Sciences
• Lupin Ltd.
• Mochida Pharmaceutical Co., Ltd.
• Mylan Pharmaceutical Pvt. Ltd.
• Neovacs SA
• Nogra Pharma Limited
• NovaMedica LLC
• Novartis International AG
• Osiris Therapeutics, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• PAR Pharmaceutical Companies, Inc.
• PendoPharm, Inc.
• Perrigo Company PLC
• Pfenex, Inc.
• Pfizer, Inc.
• Pharmascience Inc.
• Pluristem Therapeutics, Inc.
• Qu Biologics Inc.
• Quest Diagnostics, Inc.
• RedHill Biopharma Ltd.
• Reliance Life Sciences
• Salix Pharmaceuticals, Inc.
• Sandoz International GmbH
• Sanofi
• Sequella, Inc.
• Soligenix, Inc.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Toray Industries, Inc.
• Torrent Pharmaceuticals Ltd.
• UCB SA
• Zeria Pharmaceutical Co., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.